CA2082507A1 - Targeted protection from cytotoxins - Google Patents

Targeted protection from cytotoxins

Info

Publication number
CA2082507A1
CA2082507A1 CA002082507A CA2082507A CA2082507A1 CA 2082507 A1 CA2082507 A1 CA 2082507A1 CA 002082507 A CA002082507 A CA 002082507A CA 2082507 A CA2082507 A CA 2082507A CA 2082507 A1 CA2082507 A1 CA 2082507A1
Authority
CA
Canada
Prior art keywords
antagonist
conjugate
cell
cytotoxin
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002082507A
Other languages
English (en)
French (fr)
Inventor
George Y. Wu
Catherine H. Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2082507A1 publication Critical patent/CA2082507A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Butt Welding And Welding Of Specific Article (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002082507A 1990-05-11 1991-05-10 Targeted protection from cytotoxins Abandoned CA2082507A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52265390A 1990-05-11 1990-05-11
US522,653 1990-05-11

Publications (1)

Publication Number Publication Date
CA2082507A1 true CA2082507A1 (en) 1991-11-12

Family

ID=24081756

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002082507A Abandoned CA2082507A1 (en) 1990-05-11 1991-05-10 Targeted protection from cytotoxins

Country Status (5)

Country Link
EP (1) EP0538268A4 (ja)
JP (1) JPH05508398A (ja)
AU (1) AU652939B2 (ja)
CA (1) CA2082507A1 (ja)
WO (1) WO1991017761A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5490991A (en) * 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
DK0594803T3 (da) * 1992-03-23 2004-03-08 Kenneth Naoyuki Matsumura Sammensætning til reduktion af bivirkninger af et lægemiddel
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
JPH09510696A (ja) * 1994-01-11 1997-10-28 ターゲテック インコーポレイテッド 肝細胞を標的とする薬物結合体
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
DE69838584T2 (de) 1997-08-04 2008-06-26 Cell Genesys, Inc., Foster City Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
GB0916749D0 (en) 2009-09-23 2009-11-04 Mologic Ltd Peptide cleaning agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2579497B2 (ja) * 1987-09-07 1997-02-05 オリエンタル酵母工業株式会社 肝臓疾患診断剤
AU8628291A (en) * 1990-09-25 1992-04-15 University Of Connecticut, The Prolonging expression of polynucleotides introduced into a cell

Also Published As

Publication number Publication date
JPH05508398A (ja) 1993-11-25
AU7902691A (en) 1991-12-10
AU652939B2 (en) 1994-09-15
EP0538268A4 (en) 1993-05-12
WO1991017761A1 (en) 1991-11-28
EP0538268A1 (en) 1993-04-28

Similar Documents

Publication Publication Date Title
EP0276278B1 (en) Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4902505A (en) Chimeric peptides for neuropeptide delivery through the blood-brain barrier
Masquelier et al. Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice
CN100579577C (zh) 使用细胞脱唾液酸决定簇和糖缀合物将细胞靶向组织和器官的方法和组合物
EP0137457B1 (en) Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
EP0259904B1 (en) Advanced anticancer therapy and cytotoxic medicaments for its implementation
US5346696A (en) Asialoglycoprotein - conjugated medicinal agent
US7238340B1 (en) Monoamine, diamide, thiol-containing metal chelating agents
US20030035804A1 (en) Drug complex for treatment of metastatic prostate cancer
US20030119724A1 (en) Ligands to enhance cellular uptake of biomolecules
JP3117218B2 (ja) 環状ヘキサペプチド・ソマトスタチン・アナログ
JPH10501241A (ja) 造影用テクネチウム−９９ｍ標識ペプチド
AU760211C (en) Hemoglobin-haptoglobin complexes
Stein et al. Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides
CA2082507A1 (en) Targeted protection from cytotoxins
Alsenz et al. Oral absorption of peptides through the cobalamin (vitamin B12) pathway in the rat intestine
Fiume et al. Galactosylated poly (L-lysine) as a hepatotropic carrier of 9-β-D-arabinofuranosyladenine 5'-monophosphate
RO120711B1 (ro) Reactivi de legare a receptorului de calcitonină şi variante marcate ale acestora
US20020119095A1 (en) Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours
EP0527056A1 (en) Novel reagent for tumour imaging and therapy
Ghanem et al. Human melanoma targeting with α-MSH-melphalan conjugate
Fiume et al. Targeting of antiviral drugs by coupling with protein carriers
Smith-Jones et al. Synthesis, biodistribution and renal handling of various chelate-somatostatin conjugates with metabolizable linking groups
US20060141019A1 (en) Liposome
Sako et al. Pharmacokinetics of 11 C-BCNU in experimental brain tumor

Legal Events

Date Code Title Description
FZDE Dead